GENE ONLINE|News &
Opinion
Blog

WuXi Biologics Acquires Bayer’s Drug Manufacturing Facility in Wuppertal

by Tyler Chen
Share To

Following the Bayer manufacturing plant buyout in Leverkusen, Germany in January, Shanghai-based WuXi Biologics is now going to end the year with another plant acquisition from Bayer.

 

$ 183 Million Buyout

On December 21, WuXi Biologics entered into an agreement with Bayer for obtaining the Drug Substance manufacturing site at Wuppertal with a deal close to $183.3 million (€150 million). Both parties are planning on initiating a long-term sublease agreement and transition service contract.

It is the second time in 2020, WuXi Biologics gains a pharmaceutical factory in Germany.

 

The Role of Manufacturing Site in Wuppertal

MFG19 located in Wuppertal, Germany is around 30,000 square meters and equipped with 3x1000L perfusion and 6x2000L fed-batch capacity with independent downstream suites.

Purchase of MFG19 will complement the Leverkusen plant (DP7) to strengthen its supply chain to deliver more COVID-19 vaccines and other biologics. Also, MFG19 will be used for commercial manufacturing to meet the increasing demand globally.

Both procured sites are estimated to get into motion by 2021, and the transaction is expected to close in the first half of 2021.

 

About WuXi

WuXi Biologics provides a proprietary one-stop open-access biologics technology platform. It’s used to discover, develop, and manufacture biologics from concept to manufacturing.

WuXi Biologics has around 286 integrated projects by June 30. 141 projects are in the pre-clinical development stage, 125 in early-phase clinical trials, 19 projects in Phase 3 trials, and one is currently in the manufacturing stage.

By Tyler Chen

Related Article: Is Bayer’s Entry to the Gene Therapy Market Worth its Investment?

References
  1. https://www.wuxibiologics.com/News_Media-Press_Release-2020-12_21_WuXi_Biologics_to_Acquire_Drug_Substance_Facility_in_Wuppertal_Germany_from_Bayer.html
  2. https://media.bayer.com/baynews/baynews.nsf/id/Bayer-and-WuXi-Biologics-enter-into-an-agreement-on-a-Leverkusen-drug-product-plant

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
BIOSECURE Act Absent in Key U.S. Defense Bill—Slim Chance of Passing December 20 Resolution
2024-12-20
Bayer’s NUBEQA: Breakthrough in Prostate Cancer with 46% Risk Reduction and Future FDA Expansion Plans
2024-09-19
Novo Nordisk’s CLARION-CKD Trial Shut Down After Unsuccessful Results Causing Impairment Loss
2024-07-03
LATEST
2025 Starts with a Jolt: Layoffs Hit the Life Sciences Industry Ahead of JPM
2025-01-16
Eli Lilly Steals the Spotlight at JPM 2025 with $2.5 Billion Power Move Acquisition
2025-01-16
Pre-JPM 2025: The Quiet Deals You May Have Missed Before the Big Show
2025-01-16
JPM 2025’s Billion Dollar Deal – GSK Bids Big in GI Cancer
2025-01-15
Kate Middleton, Princess of Wales: Cancer Journey and Recovery
2025-01-15
What is Tech Giant NVIDIA Doing Now? Latest Collabs Building the Healthcare Puzzle, One Byte at a Time
2025-01-15
EY Predicts Smarter, Smaller M&A in Biotech and Pharma for 2025
2025-01-15
EVENT
2025-01-13
JP Morgan Healthcare Conference
San Francisco, California
2025-02-05
Precision Medicine World Conference 2025
Santa Clara, California
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
Scroll to Top